Tracking how larotrectinib works for NTRK fusion cancers in routine care
Treatments studied
Part of Cancer clinical trials.
This study follows people with cancers that have an NTRK gene fusion to learn how safe and effective larotrectinib is during everyday treatment. It may help confirm whether this medicine works well in real-world patients and side effects stay manageable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a solid tumor (not blood cancer) that has an NTRK gene fusion
- Your diagnosis must be found by approved genetic tests (or by pan-TRK IHC plus another confirmatory test)
- You (or your doctor) are starting larotrectinib as part of routine care before enrolling
- You are expected to live at least about 3 months
- If you are pregnant, you cannot join, and people who are already treated with larotrectinib (or another TRK-blocking medicine) cannot join
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is for people with advanced or returning solid tumors that have specific gene changes called NTRK gene fusions. It looks at patients who are already being treated with larotrectinib as part of normal care, to understand this treatment in real life.
This trial studies larotrectinib, a targeted medicine, in people with solid tumors that have extra copies (amplification) of the NTRK1, NTRK2, or NTRK3 gene. It’s for cancers that have already been treated with standard options or where standard options are unlikely to help.
This Phase 2 trial tests larotrectinib (a targeted medicine) to help radioactive iodine (RAI) work better in people with differentiated thyroid cancer that has an NTRK gene fusion. It may improve how much thyroid cancer the RAI can reach and shrink.
This trial tests larotrectinib, a targeted cancer medicine, in children and teens with newly diagnosed high-grade brain glioma that has an NTRK fusion. It may help shrink or control tumors by targeting a specific genetic change in the cancer.
This trial tests a new daily pill (CG001419) for people with advanced solid tumors that have specific changes in the NTRK gene or TRK protein. The study aims to see if the drug is safe and effective, especially in those whose cancers have not responded to other treatments.
This early-phase study tests repotrectinib, a targeted medicine, in children and young adults whose tumors have specific gene changes involving ROS1 or NTRK. It may help shrink advanced cancers that carry these gene alterations.
Hear when a new Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.